SLC5A2 and type 2 diabetes mellitus: Analysis performed by European Medical Agency presented 102 cases of serious diabetic ketoacidosis in patients on SGLT2 inhibitor treatment (canagliflozin, dapagliflozin, or empagliflozin) for T2DM (diabetes mellitus type 2).